Works by Rodríguez-Otero, Paula

Results: 30
    1
    2

    Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.

    Published in:
    Cancers, 2021, v. 13, n. 19, p. 4924, doi. 10.3390/cancers13194924
    By:
    • Puig, Noemí;
    • Flores-Montero, Juan;
    • Burgos, Leire;
    • Cedena, María-Teresa;
    • Cordón, Lourdes;
    • Pérez, José-Juan;
    • Sanoja-Flores, Luzalba;
    • Manrique, Irene;
    • Rodríguez-Otero, Paula;
    • Rosiñol, Laura;
    • Martínez-López, Joaquín;
    • Mateos, María-Victoria;
    • Lahuerta, Juan-José;
    • Bladé, Joan;
    • San Miguel, Jesús F.;
    • Orfao, Alberto;
    • Paiva, Bruno
    Publication type:
    Article
    3

    Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

    Published in:
    Advances in Therapy, 2024, v. 41, n. 4, p. 1576, doi. 10.1007/s12325-024-02797-x
    By:
    • Einsele, Hermann;
    • Moreau, Philippe;
    • Bahlis, Nizar;
    • Bhutani, Manisha;
    • Vincent, Laure;
    • Karlin, Lionel;
    • Perrot, Aurore;
    • Goldschmidt, Hartmut;
    • van de Donk, Niels W. C. J.;
    • Ocio, Enrique M.;
    • Martinez-Lopez, Joaquin;
    • Rodríguez-Otero, Paula;
    • Dytfeld, Dominik;
    • Diels, Joris;
    • Strulev, Vadim;
    • Haddad, Imene;
    • Renaud, Thomas;
    • Ammann, Eric;
    • Cabrieto, Jedelyn;
    • Perualila, Nolen
    Publication type:
    Article
    4
    5

    A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00652-2
    By:
    • Encinas, Cristina;
    • Hernandez-Rivas, José-Ángel;
    • Oriol, Albert;
    • Rosiñol, Laura;
    • Blanchard, María-Jesús;
    • Bellón, José-María;
    • García-Sanz, Ramón;
    • de la Rubia, Javier;
    • de la Guía, Ana López;
    • Jímenez-Ubieto, Ana;
    • Jarque, Isidro;
    • Iñigo, Belén;
    • Dourdil, Victoria;
    • de Arriba, Felipe;
    • Pérez-Ávila, Clara Cuéllar;
    • Gonzalez, Yolanda;
    • Hernández, Miguel-Teodoro;
    • Bargay, Joan;
    • Granell, Miguel;
    • Rodríguez-Otero, Paula
    Publication type:
    Article
    6

    An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 11, p. 1864, doi. 10.1080/10428194.2023.2235042
    By:
    • Rodríguez Otero, Paula;
    • Towle, Kevin;
    • Cope, Shannon;
    • Caisip, Clyde;
    • Davies, Faith E.;
    • Delforge, Michel;
    • Weisel, Katja;
    • Marshall, Thomas S.;
    • Karampampa, Korinna;
    • Ayers, Dieter;
    • Mojebi, Ali;
    • Braverman, Julia;
    • Farrell, James;
    • Dhanda, Devender
    Publication type:
    Article
    7

    Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 8, p. 1850, doi. 10.1080/10428194.2020.1747066
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios;
    • Moreau, Philippe;
    • Yagci, Munci;
    • Larocca, Alessandra;
    • Kanate, Abraham S.;
    • Vural, Filiz;
    • Cascavilla, Nicola;
    • Basu, Supratik;
    • Johnson, Peter;
    • Byeff, Peter;
    • Hus, Marek;
    • Rodríguez-Otero, Paula;
    • Muelduer, Ercan;
    • Anttila, Pekka;
    • Hayden, Patrick J.;
    • Krauth, Maria-Theresa;
    • Lucio, Paulo;
    • Ben-Yehuda, Dina;
    • Mendeleeva, Larisa
    Publication type:
    Article
    8

    Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. e844, doi. 10.1016/j.clml.2022.04.024
    By:
    • Tamariz-Amador, Luis-Esteban;
    • Rodríguez-Otero, Paula;
    • Jiménez-Ubieto, Ana;
    • Rosiñol, Laura;
    • Oriol, Albert;
    • Ríos, Rafael;
    • Sureda, Anna;
    • Blanchard, Maria Jesus;
    • Hernández, Miguel Teodoro;
    • Perianes, Valentin Cabañas;
    • Jarque, Isidro;
    • Bargay, Juan;
    • Gironella, Mercedes;
    • Arriba, Felipe De;
    • Palomera, Luis;
    • Gonzalez-Montes, Yolanda;
    • Martí, Josep M.;
    • Krsnik, Isabel;
    • Arguiñano, José María;
    • González, María Esther
    Publication type:
    Article
    9

    Corrigendum.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 545, doi. 10.1016/j.clml.2022.03.011
    By:
    • Ghobrial1, Irene M.;
    • Rodríguez-Otero, Paula;
    • Koh, Youngil;
    • Martínez-López, Joaquín;
    • Parmar, Gurdeep;
    • Prince, Miles;
    • Quach, Hang;
    • Rubia, Javier de la;
    • Hermansen, Emil;
    • Hungria, Vania;
    • Besisik, Sevgi Kalayoglu;
    • Kim, Jin Seok;
    • Leleu, Xavier;
    • Peceliunas, Valdas;
    • Schjesvold, Fredrik;
    • Dubin, Franck;
    • Devisme, Christine;
    • Lepine, Lucie;
    • Macé, Sandrine;
    • Oprea, Corina
    Publication type:
    Article
    10

    P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S160, doi. 10.1016/S2152-2650(21)02346-6
    By:
    • Terpos, Evangelos;
    • Badros, Ashraf Z.;
    • Popat, Rakesh;
    • Rodríguez-Otero, Paula;
    • Farooq, Asim V.;
    • Jeng, Bennie;
    • Esposti, Simona Degli;
    • Lewis, Eric;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Palumbo, Antonio;
    • Trudel, Suzanne;
    • Jadhav, Vinay
    Publication type:
    Article
    11

    P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S156, doi. 10.1016/S2152-2650(21)02339-9
    By:
    • Richardson, Paul G.;
    • Trudel, Suzanne;
    • Callander, Natalie S.;
    • Nooka, Ajay;
    • Song, Kevin;
    • Uttervall, Katarina;
    • Minnema, Monique C.;
    • Rodríguez-Otero, Paula;
    • Struemper, Herbert;
    • Yeakey, Anne;
    • de Oca, Rocio Montes;
    • Smith, L. Mary;
    • Jackson, Nicola;
    • Kaisermann, Morrys;
    • Im, Ellie;
    • Basile, Frank G.;
    • Ahlers, Christoph M.;
    • Holkova, Beata;
    • Gupta, Ira;
    • Kremer, Brandon E.
    Publication type:
    Article
    12

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    13

    P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S139, doi. 10.1016/S2152-2650(21)02314-4
    By:
    • Ayers, Dieter;
    • Cope, Shannon;
    • Dhanda, Devender S.;
    • Towle, Kevin;
    • Mojebi, Ali;
    • Delforge, Michel;
    • Rodríguez-Otero, Paula;
    • Trudel, Suzanne;
    • Weisel, Katja;
    • Zamagni, Elena;
    • Hari, Parameswaran
    Publication type:
    Article
    14

    P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02264-3
    By:
    • Ghobrial, Irene;
    • Rodríguez-Otero, Paula;
    • Youngil Koh;
    • Martínez-López, Joaquín;
    • Parmar, Gurdeep;
    • Prince, Miles;
    • Hang Quach;
    • de la Rubia, Javier;
    • Hermansen, Emil;
    • Hungria, Vania;
    • Besisik, Sevgi Kalayoglu;
    • Jin Seok Kim;
    • Leleu, Xavier;
    • Peceliunas, Valdas;
    • Schjesvold, Fredrik;
    • Dubin, Franck;
    • Devisme, Christine;
    • Lepine, Lucie;
    • Macé, Sandrine;
    • Oprea, Codina
    Publication type:
    Article
    15

    OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S16, doi. 10.1016/S2152-2650(21)02099-1
    By:
    • Donk, Niels W.C.J. van de;
    • Krishnan, Amrita;
    • Oriol, A;
    • Berdeja, Jesus G.;
    • Rodríguez-Otero, Paula;
    • Askari, Elham;
    • Mateos, María-Victoria;
    • Minnema, Monique C.;
    • Costa, Luciano;
    • Verona, Raluca;
    • Girgis, Suzette;
    • Prior, Thomas;
    • Hilder, Brandi;
    • Russell, Jeffery;
    • Goldberg, Jenna;
    • Chari, Ajai
    Publication type:
    Article
    16

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    17

    OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
    By:
    • Ocio, Enrique;
    • Perrot, Aurore;
    • Bories, Pierre;
    • San-Miguel, Jesús F.;
    • Blau, Igor W.;
    • Karlin, Lionel;
    • Martínez-López, Joaquín;
    • Pönisch, Wolfram;
    • Bringhen, Sara;
    • Marcatti, Magda;
    • Mateos, María-Victoria;
    • Rodríguez-Otero, Paula;
    • Le Roux, Nadia;
    • Dong, Yvonne;
    • Macé, Sandrine;
    • Fitzmaurice, Thomas;
    • Moreau, Philippe
    Publication type:
    Article
    18

    MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Blade, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    19

    MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
    By:
    • Richardson, Paul G;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemi;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    20

    Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Bladé, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    21

    Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
    By:
    • Richardson, Paul G.;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemí;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    22

    Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e352, doi. 10.1016/j.clml.2019.09.582
    By:
    • Richardson, Paul G.;
    • Mateos, Maria-Victoria;
    • Rodríguez-Otero, Paula;
    • Norkin, Maxim;
    • Larocca, Alessandra;
    • Hassoun, Hani;
    • Alegre, Adrian;
    • Paner, Agne;
    • Leleu, Xavier;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Harmenberg, Johan;
    • Byrne, Catriona;
    • Zubair, Hanan;
    • Thuresson, Sara;
    • Blade, Joan
    Publication type:
    Article
    23

    Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e351, doi. 10.1016/j.clml.2019.09.580
    By:
    • Garcés, Juan José;
    • Bretones, Gabriel;
    • Burgos, Leire;
    • Valdés-Mas, Rafael;
    • Alignani, Diego;
    • Puente, Diana Álvarez;
    • Goicoechea, Ibai;
    • García-Álvarez, Miguel;
    • Garate, Sonia;
    • Rodríguez, Idoia;
    • Calasanz, Maria-Jose;
    • Rodríguez-Otero, Paula;
    • Tamayo, Rafael Ríos;
    • Martinez-Lopez, Joaquin;
    • Millacoy, Pamela;
    • Bernal, Luis Palomera;
    • Del Orbe, Rafael;
    • Montaña, Albert Pérez;
    • Agirre, Xabier;
    • Flores-Montero, Juan
    Publication type:
    Article
    24

    Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells.

    Published in:
    British Journal of Haematology, 2024, v. 205, n. 4, p. 1346, doi. 10.1111/bjh.19589
    By:
    • Ortiz de Landazuri, Iñaki;
    • Oliver‐Caldés, Aina;
    • Español‐Rego, Marta;
    • Agulló, Cristina;
    • Contreras, María Teresa;
    • Zabaleta, Aintzane;
    • Puig, Noemí;
    • Cabañas, Valentín;
    • González‐Calle, Verónica;
    • Zugasti, Inés;
    • Inogés, Susana;
    • Rodríguez Otero, Paula;
    • Martin‐Antonio, Beatriz;
    • Reguera, Juan Luis;
    • López‐Diaz de Cerio, Ascensión;
    • Aróstegui, Juan Ignacio;
    • Uribe‐Herranz, Mireia;
    • Benítez‐Ribas, Daniel;
    • Rodríguez‐Lobato, Luis Gerardo;
    • González, Europa Azucena
    Publication type:
    Article
    25

    Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.

    Published in:
    British Journal of Haematology, 2021, v. 192, n. 3, p. 522, doi. 10.1111/bjh.16788
    By:
    • Ocio, Enrique M.;
    • Motlló, Cristina;
    • Rodríguez‐Otero, Paula;
    • Martínez‐López, Joaquín;
    • Cejalvo, Mª José;
    • Martín‐Sánchez, Jesús;
    • Bladé, Joan;
    • García‐Malo, Mª Dolores;
    • Dourdil, Mª Victoria;
    • García‐Mateo, Aránzazu;
    • Arriba, Felipe;
    • García‐Sanz, Ramón;
    • Rubia, Javier;
    • Oriol, Albert;
    • Lahuerta, Juan‐José;
    • San‐Miguel, Jesús F.;
    • Mateos, María‐Victoria
    Publication type:
    Article
    26

    Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study.

    Published in:
    British Journal of Haematology, 2019, v. 186, n. 5, p. e117, doi. 10.1111/bjh.15946
    By:
    • Mateos, Maria‐Victoria;
    • Orlowski, Robert Z.;
    • Ocio, Enrique M.;
    • Rodríguez‐Otero, Paula;
    • Reece, Donna;
    • Moreau, Philippe;
    • Munshi, Nikhil;
    • Avigan, David E.;
    • Siegel, David S.;
    • Ghori, Razi;
    • Farooqui, Mohammed Z. H.;
    • Marinello, Patricia;
    • San-Miguel, Jesus
    Publication type:
    Article
    27

    Melflufen for relapsed and refractory multiple myeloma.

    Published in:
    Expert Opinion on Investigational Drugs, 2020, v. 29, n. 10, p. 1069, doi. 10.1080/13543784.2020.1808884
    By:
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Leleu, Xavier;
    • Hajek, Roman;
    • Hassoun, Hani;
    • Rodríguez-Otero, Paula;
    • Paner, Agne;
    • Schjesvold, Fredrik H.;
    • Gullbo, Joachim;
    • Richardson, Paul G.
    Publication type:
    Article
    28
    29

    Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia.

    Published in:
    PLoS ONE, 2011, v. 6, n. 2, p. 1, doi. 10.1371/journal.pone.0017012
    By:
    • Vilas-Zornoza, Amaia;
    • Agirre, Xabier;
    • Martín-Palanco, Vanesa;
    • Martín-Subero, José Ignacio;
    • José-Eneriz, Edurne San;
    • Garate, Leire;
    • lvarez, Sara Á;
    • Miranda, Estíbaliz;
    • Rodríguez-Otero, Paula;
    • Rifón, José;
    • Torres, Antonio;
    • Calasanz, María José;
    • Cigudosa, Juan Cruz;
    • Román-Gómez, José;
    • sper, Felipe Pró
    Publication type:
    Article
    30

    Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).

    Published in:
    Leukemia & Lymphoma, 2007, v. 48, n. 12, p. 2461, doi. 10.1080/10428190701671044
    By:
    • García-Muñoz, Ricardo;
    • Galar, Alicia;
    • Moreno, Cristina;
    • Rodríguez-Otero, Paula;
    • Panizo-Morgado, Elena;
    • Ponz-Sarvisê, Mariano;
    • Fernandez-Alonso, Mirian;
    • Rubio, Manuel;
    • Merino, Juana;
    • Cuesta, Braulia;
    • Panizol, Carlos;
    • Prosper, Felipe
    Publication type:
    Article